Yahoo Finance OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript
OmniAb, Inc. (NASDAQ:OABI) Q3 2023 Earnings Call Transcript November 14, 2023
Matthew Foehr: Okay, great, we're at 8 am Pacific Time, 11 am Eastern time. So we will kick it off. Good morning everyone. I'm Matt Foehr, CEO of OmniAb, and I want to thank you all for joining our first Research and Technology Event. We are presenting today from NASDAQ's Entrepreneurial Center, in Downtown San Francisco, which is just a short drive across the Bay Bridge from our headquarters and labs over in Emeryville. It's been just over a year since OmniAb became an independent publicly traded company listed on the NASDAQ Exchange. And I want to thank the NASDAQ team here in San Francisco and back in New York, but especially the team here in San Francisco for hosting us today and furnishing this great space for our event this morning.
But before I begin, I'd like to remind you that we'll be making forward-looking statements during our presentations. These forward-looking statements, of course, carry risks and uncertainties and actual results may be different from those that are projected. So I'd urge investors to please consult today's earnings release as well as our SEC filings for more information on these risks. So again, welcome. I'm going to provide some opening remarks this morning, some updates on the business and also give a bit of a roadmap to today's presentations. But before I do, I wanted to introduce you to our presenters. We've got a wider cross-section of management. I'm excited that investors and analysts get the chance to meet more of our management and leadership team here.
So you'll see presentations from Todd Pettingill, who is our VP of Business Development and Strategy. Todd's been with the OmniAb business really since the beginning of forming the foundation of what has now become OmniAb. He played a critical role in all six of the acquisitions of the company and technology acquisitions that we did in the less than the six year period to form what is now the foundation of the business of OmniAb. Bill Harriman, heads our antibody discovery. Bill was a Founder of Crystal Bioscience, which was the innovator and inventor of OmniChicken. Bill's had a really illustrious career in the antibody discovery space, is also the inventor of the GEM Assay, which is a part of our technology. And Bill has the honors of doing the OmnidAb launch today, and you'll hear more about that as I run through the agenda.
Bob Chen runs our Discovery Systems. Bob joined us when we acquired xCella Biosciences. Bob was the Co-Founder of xCella. He Co-Founded it along with Dr. Jennifer Cochran, who also sits on our Board of Directors. The xCella business was spun out of the Stanford School of Engineering, and Bob is an inventor of our exploration technology, which has become a key part of our business as well. And you'll also get to meet Doug Krafte. Doug is a well-known individual in the scientific circles around ion channels and transporters. He has a long history of first scientific -- first around the ion channel and transporter space and heads our Ion Channel AND Transporter Team based out in Durham. And then you'll also get to meet Kurt. Obviously, many of the investors on the line and analysts know Kurt very well.
Kurt joined us not long before the split, when we split the business off and became an independent publicly traded company. A long career in biotech and technology, longest of which was at Amgen for many years, heading their European finance operations. So excited that you'll get a chance to meet all of these colleagues who I'm honored to work with today. Today's agenda, again, I'll provide some opening remarks. Todd is going to give an update on creating value for partners. That's something obviously is very important to us. And Bill will be launching the OmnidAb technology today. We'll talk a lot about that, get into the science, get into where it fits in the industry and why it's important. Bob will highlight how we enhance discovery with OmniDeep, which is our suite of in silico tools that are woven throughout our technology stack.
See also 12 Best Performing S&P 500 Stocks in the Last 10 Years and 25 Countries with Highest Percentage of Females.
To continue reading the Q&A session, please click here.
